头颈部鳞状细胞癌
肿瘤微环境
免疫系统
细胞毒性T细胞
医学
癌症研究
CD8型
肿瘤进展
肿瘤浸润淋巴细胞
趋化因子
FOXP3型
免疫学
癌症
生物
内科学
头颈部癌
体外
生物化学
作者
Janis V. de la Iglesia,Robbert J.C. Slebos,Laura Martin‐Gomez,Xuefeng Wang,Jamie K. Teer,Aik Choon Tan,Travis Gerke,Garrick Aden-Buie,Tessa van Veen,Jude Masannat,Ritu Chaudhary,Feifei Song,Michelle Fournier,Erin M. Siegel,Matthew B. Schabath,J. Trad Wadsworth,Jimmy J. Caudell,Louis Harrison,Bruce M. Wenig,José R. Conejo-García
标识
DOI:10.1158/1078-0432.ccr-19-1769
摘要
Patients with head and neck squamous cell carcinoma (HNSCC) who actively smoke during treatment have worse survival compared with never-smokers and former-smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least in part, due to ongoing suppression of immune response. We characterized the tumor immune microenvironment (TIM) of HNSCC in a retrospective cohort of 177 current, former, and never smokers.Tumor specimens were subjected to analysis of CD3, CD8, FOXP3, PD-1, PD-L1, and pancytokeratin by multiplex immunofluorescence, whole-exome sequencing, and RNA sequencing. Immune markers were measured in tumor core, tumor margin, and stroma.Our data indicate that current smokers have significantly lower numbers of CD8+ cytotoxic T cells and PD-L1+ cells in the TIM compared with never- and former-smokers. While tumor mutation burden and mutant allele tumor heterogeneity score do not associate with smoking status, gene-set enrichment analyses reveal significant suppression of IFNα and IFNγ response pathways in current smokers. Gene expression of canonical IFN response chemokines, CXCL9, CXCL10, and CXCL11, are lower in current smokers than in former smokers, suggesting a mechanism for the decreased immune cell migration to tumor sites.These results suggest active tobacco use in HNSCC has an immunosuppressive effect through inhibition of tumor infiltration of cytotoxic T cells, likely as a result of suppression of IFN response pathways. Our study highlights the importance of understanding the interaction between smoking and TIM in light of emerging immune modulators for cancer management.
科研通智能强力驱动
Strongly Powered by AbleSci AI